Literature DB >> 9916088

Differential posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans.

M J Calcutt1, M F Kim, A B Karpas, P F Mühlradt, K S Wise.   

Abstract

The malp gene of Mycoplasma fermentans is shown to occur in single copy but to encode two discrete translated forms of lipid-modified surface protein that can be differentially expressed on isolates within this species: MALP-2, a 14-amino-acid (2-kDa) lipopeptide with potent macrophage-stimulatory activity (P. F. Mühlradt, M. Kiess, H. Meyer, R. Süssmuth, and G. Jung, J. Exp. Med. 185:1951-1958, 1997), and MALP-404, an abundant, full-length (404-amino-acid) surface lipoprotein of 41 kDa, previously designated P41 (K. S. Wise, M. F. Kim, P. M. Theiss, and S.-C. Lo, Infect. Immun. 61:3327-3333, 1993). The sequences, transcripts, and translation products of malp were compared between clonal isolates of strains PG18 (known to express P41) and II-29/1 (known to express high levels of MALP-2). Despite conserved malp DNA sequences containing full-length open reading frames and expression of full-length monocistronic transcripts in both isolates, Western blotting using a monoclonal antibody (MAb) to the N-terminal MALP-2 peptide revealed marked differences in the protein products expressed. Whereas PG18 expressed abundant MALP-404 with detectable MALP-2, II-29/1 revealed no MALP-404 even in samples containing a large comparative excess of MALP-2. Colony immunoblots with the MAb showed uniform surface expression of MALP-2 in II-29/1 populations. A second MAb to an epitope of MALP-404 outside the MALP-2 sequence predictably failed to stain II-29/1 colonies but uniformly stained PG18 populations. Collectively, these results provide evidence for novel posttranscriptional (probably posttranslational) processing pathways leading to differential intraspecies expression of a major lipoprotein, and a potent macrophage-activating lipopeptide, on the surface of M. fermentans. In the course of this study, a striking conserved motif (consensus, TD-G--DDKSFNQSAWE--), designated SLA, was identified in MALP-404; this motif is also distributed among selected lipoproteins and species from diverse bacterial genera, including Bacillus, Borrelia, Listeria, Mycoplasma, and Treponema. In addition, malp was shown to flank a chromosomal polymorphism. In eight isolates of M. fermentans examined, malp occurred upstream of an operon encoding the phase-variable P78 ABC transporter; but, in three of these isolates, a newly discovered insertion sequence, IS1630 (of the IS30 class), was located between these genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916088      PMCID: PMC96384     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Complete genome sequence of Mycoplasma bovis type strain PG45 (ATCC 25523).

Authors:  Kim S Wise; Michael J Calcutt; Mark F Foecking; Kerstin Röske; Ramana Madupu; Barbara A Methé
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

2.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

3.  Association of lipids with integral membrane surface proteins of Mycoplasma hyorhinis.

Authors:  T M Bricker; M J Boyer; J Keith; R Watson-McKown; K S Wise
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

4.  Identification of an insertion-sequence-like genetic element in the newly recognized human pathogen Mycoplasma incognitus.

Authors:  W S Hu; R Y Wang; R S Liou; J W Shih; S C Lo
Journal:  Gene       Date:  1990-09-01       Impact factor: 3.688

5.  Sequence and TnphoA analysis of a Mycoplasma hyorhinis protein with membrane export function.

Authors:  D Yogev; R Watson-McKown; M A McIntosh; K S Wise
Journal:  J Bacteriol       Date:  1991-03       Impact factor: 3.490

6.  MDHM, a macrophage-stimulatory product of Mycoplasma fermentans, leads to in vitro interleukin-1 (IL-1), IL-6, tumor necrosis factor, and prostaglandin production and is pyrogenic in rabbits.

Authors:  P F Mühlradt; U Schade
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Localization of an immunodominant 64 kDa lipoprotein (LP 64) in the membrane of Mycoplasma gallisepticum and its role in cytadherence.

Authors:  M H Forsyth; M E Tourtellotte; S J Geary
Journal:  Mol Microbiol       Date:  1992-08       Impact factor: 3.501

8.  The Vlp system of Mycoplasma hyorhinis: combinatorial expression of distinct size variant lipoproteins generating high-frequency surface antigenic variation.

Authors:  R Rosengarten; K S Wise
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

9.  Mycoplasma fermentans-derived high-molecular-weight material induces interleukin-6 release in cultures of murine macrophages and human monocytes.

Authors:  H Quentmeier; E Schmitt; H Kirchhoff; W Grote; P F Mühlradt
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 10.  Interactions between mycoplasmas and the immune system.

Authors:  E Ruuth; F Praz
Journal:  Immunol Rev       Date:  1989-12       Impact factor: 12.988

View more
  27 in total

1.  P48 major surface antigen of Mycoplasma agalactiae is homologous to a malp product of Mycoplasma fermentans and belongs to a selected family of bacterial lipoproteins.

Authors:  S Rosati; S Pozzi; P Robino; B Montinaro; A Conti; M Fadda; M Pittau
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Characterization of a multigene family undergoing high-frequency DNA rearrangements and coding for abundant variable surface proteins in Mycoplasma agalactiae.

Authors:  M D Glew; L Papazisi; F Poumarat; D Bergonier; R Rosengarten; C Citti
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 4.  Pathogenesis of Adamantiades-Behçet's disease.

Authors:  Christos C Zouboulis; Tobias May
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

5.  Evolution of an autotransporter: domain shuffling and lateral transfer from pathogenic Haemophilus to Neisseria.

Authors:  J Davis; A L Smith; W R Hughes; M Golomb
Journal:  J Bacteriol       Date:  2001-08       Impact factor: 3.490

6.  Homologue of macrophage-activating lipoprotein in Mycoplasma gallisepticum is not essential for growth and pathogenicity in tracheal organ cultures.

Authors:  Philip F Markham; Anna Kanci; György Czifra; Bo Sundquist; Peter Hains; Glenn F Browning
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

7.  Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2.

Authors:  A Kaufmann; P F Mühlradt; D Gemsa; H Sprenger
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Complement activation in Mycoplasma fermentans-induced mycoplasma clearance from infected cells: probing of the organism with monoclonal antibodies against M161Ag.

Authors:  S Kikkawa; M Matsumoto; T Sasaki; M Nishiguchi; K Tanaka; K Toyoshima; T Seya
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  Proteolytic processing of the Mycoplasma hyopneumoniae cilium adhesin.

Authors:  Steven P Djordjevic; Stuart J Cordwell; Michael A Djordjevic; Jody Wilton; F Chris Minion
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Molecular genetic analysis of ICEF, an integrative conjugal element that is present as a repetitive sequence in the chromosome of Mycoplasma fermentans PG18.

Authors:  Michael J Calcutt; Michelle S Lewis; Kim S Wise
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.